Department of Clinical Laboratory, the First Affiliated Hospital of Anhui Medical University, Anhui, China.
Department of Clinical Laboratory, the First Affiliated Hospital of Anhui Medical University, Anhui, China; Institute of Pediatrics, Children's Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.
Diagn Microbiol Infect Dis. 2024 Nov;110(3):116480. doi: 10.1016/j.diagmicrobio.2024.116480. Epub 2024 Aug 6.
The apical membrane antigen-1 (AMA-1) is a crucial target for malaria management and prevention strategies. While the immunogenicity of AMA-1 has been extensively studied for Plasmodium falciparum and Plasmodium vivax, there is a notable scarcity of information for Plasmodium malariae. In this study, recombinant PmAMA-1 was expressed in Escherichia coli, and its integrity was confirmed via western blotting and indirect immunofluorescence assays. Immunization of BALB/c mice with rPmAMA-1 emulsified in Freund's adjuvant resulted in significantly elevated specific IgG antibodies, predominantly IgG1. The immune response exhibited Th1, Th2, and Th17 phenotypes, with a notable Th1 bias. Antisera from immunized mice effectively recognized native PmAMA-1 on P. malariae. These results suggest that PmAMA-1 is a promising target for both vaccine development and diagnostic applications for P. malariae infections, offering dual preventive and diagnostic benefits in malaria control.
顶膜蛋白抗原-1(AMA-1)是疟疾管理和预防策略的重要靶标。虽然已经对恶性疟原虫和间日疟原虫的 AMA-1 免疫原性进行了广泛研究,但对疟原虫的信息却明显缺乏。在这项研究中,重组 PmAMA-1 在大肠杆菌中表达,并通过 Western blot 和间接免疫荧光试验证实其完整性。用弗氏佐剂乳化的 rPmAMA-1 免疫 BALB/c 小鼠导致特异性 IgG 抗体显著升高,主要是 IgG1。免疫反应表现出 Th1、Th2 和 Th17 表型,具有明显的 Th1 偏向。免疫小鼠的抗血清可有效识别恶性疟原虫上的天然 PmAMA-1。这些结果表明 PmAMA-1 是恶性疟原虫疫苗开发和诊断应用的有前途的靶标,在疟疾控制中提供了双重预防和诊断效益。